Both Anakinra and Xeljanz offer similar effectiveness, with differences in speed and duration of relief.

Both drugs have comparable safety profiles, with mild side effects that are generally well-tolerated.

Both drugs are low-risk for addiction when used properly, with minimal potential for misuse.

Anakinra has a simple once-daily dose, making it easier to stick to a treatment routine.

Both drugs have some contraindications depending on individual health conditions, but neither has major restrictions.

Both drugs are good options depending on the patient’s needs, with Anakinra better for quick relief and Xeljanz for long-term management.